JP2007520507A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520507A5
JP2007520507A5 JP2006551762A JP2006551762A JP2007520507A5 JP 2007520507 A5 JP2007520507 A5 JP 2007520507A5 JP 2006551762 A JP2006551762 A JP 2006551762A JP 2006551762 A JP2006551762 A JP 2006551762A JP 2007520507 A5 JP2007520507 A5 JP 2007520507A5
Authority
JP
Japan
Prior art keywords
acceptable salt
physiologically acceptable
inhibitor
glycopyrrolate
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006551762A
Other languages
English (en)
Japanese (ja)
Other versions
JP4700014B2 (ja
JP2007520507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/000651 external-priority patent/WO2005074982A2/en
Publication of JP2007520507A publication Critical patent/JP2007520507A/ja
Publication of JP2007520507A5 publication Critical patent/JP2007520507A5/ja
Application granted granted Critical
Publication of JP4700014B2 publication Critical patent/JP4700014B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006551762A 2004-02-06 2005-01-24 呼吸器系疾患の治療用の抗コリン作用薬及び4型ホスホジエステラーゼの組合せ剤 Expired - Fee Related JP4700014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54195504P 2004-02-06 2004-02-06
US60/541,955 2004-02-06
PCT/EP2005/000651 WO2005074982A2 (en) 2004-02-06 2005-01-24 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases

Publications (3)

Publication Number Publication Date
JP2007520507A JP2007520507A (ja) 2007-07-26
JP2007520507A5 true JP2007520507A5 (enExample) 2007-12-27
JP4700014B2 JP4700014B2 (ja) 2011-06-15

Family

ID=34837532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551762A Expired - Fee Related JP4700014B2 (ja) 2004-02-06 2005-01-24 呼吸器系疾患の治療用の抗コリン作用薬及び4型ホスホジエステラーゼの組合せ剤

Country Status (18)

Country Link
US (3) US20050175547A1 (enExample)
EP (1) EP1713471B1 (enExample)
JP (1) JP4700014B2 (enExample)
CN (2) CN100512813C (enExample)
AT (1) ATE541570T1 (enExample)
AU (1) AU2005210084B2 (enExample)
CA (1) CA2550848C (enExample)
CY (1) CY1112968T1 (enExample)
DK (1) DK1713471T3 (enExample)
ES (1) ES2381116T3 (enExample)
HR (1) HRP20120286T1 (enExample)
NO (1) NO337023B1 (enExample)
NZ (1) NZ548301A (enExample)
PL (1) PL1713471T3 (enExample)
PT (1) PT1713471E (enExample)
RU (1) RU2437658C2 (enExample)
SI (1) SI1713471T1 (enExample)
WO (1) WO2005074982A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2007524699A (ja) * 2004-02-27 2007-08-30 アルタナ ファルマ アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
RU2008119323A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
JP2011500731A (ja) * 2007-10-25 2011-01-06 メルク フロスト カナダ リミテツド 併用療法
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
DK2948148T3 (da) * 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
US9700558B2 (en) * 2013-03-15 2017-07-11 Verona Pharma Plc Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
TW201542207A (zh) * 2013-10-03 2015-11-16 Otsuka Pharma Co Ltd 嚴重氣喘治療劑
CN104586841A (zh) * 2013-10-30 2015-05-06 中国药科大学 (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
AU7455498A (en) * 1998-05-29 1999-12-20 Citizen Watch Co. Ltd. Method of subjecting ink jet printer to preuse treatment
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
CA2347856C (en) 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040028958A1 (en) 2002-06-18 2004-02-12 Total Innovative Manufacturing Llc Recyclable fire-resistant moldable batt and panels formed therefrom
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
PT1372608E (pt) 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SK14312003A3 (sk) * 2001-05-25 2004-08-03 Pfizer Inc. Inhibítor PDE4 a anticholinergné činidlo v kombinácii na liečbu obštrukčných chorôb dýchacích ciest
DE60216588T2 (de) * 2001-05-25 2007-09-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
US20040053902A1 (en) 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
CA2519679C (en) * 2003-03-28 2012-08-28 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
CA2519682A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20060155491A1 (en) 2003-07-11 2006-07-13 Peter Bode Frequency determination

Similar Documents

Publication Publication Date Title
JP2007520507A5 (enExample)
JP7623854B2 (ja) 乾燥粉末配合および使用方法
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2007520508A5 (enExample)
Dolovich et al. Aerosol drug delivery: developments in device design and clinical use
Westerman et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
RU2006132038A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
BR0317443A (pt) Medicamento pulverulento para inalação contendo um sal de tiotrópio e xinafoato de salmeterol
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
JP2014514271A5 (enExample)
NO20064161L (no) Farmasoytiske formuleringer for torrpulverinhalatorer omfattende en aktiv ingrediens med lavdoseringsstyrke
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
JP2008518007A5 (enExample)
US20230158259A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
JP2008533072A5 (enExample)
SK2302003A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
Dongare et al. An overview of recently published patents on pulmonary drug delivery devices
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
ES2917879T3 (es) Nuevo uso de aclidinio
BR0316343A (pt) Formulações pulverulentas para inalação contendo tiotrópio
BR0308984A (pt) Formulações em pó adequadas para inalação
US9539248B2 (en) Agent for ameliorating chronic obstructive pulmonary disease
Balducci et al. Drug delivery strategies for pulmonary administration of antibiotics